ArticleBMJ public health2026
Spatiotemporal and clinical characterisation of acute flaccid paralysis in Uganda, 2016-2023.
Article in BMJ public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Uganda, in line with global efforts to eradicate polio by 2026, conducts surveillance for acute flaccid paralysis (AFP) among children <15 years to enable the timely detection of poliovirus. We analysed national AFP surveillance data to characterise case demographics, spatiotemporal patterns and clinical outcomes, and to evaluate surveillance performance and progress towards eradication. Methods: We conducted a retrospective descriptive analysis of routine AFP surveillance data from 2016 to 2023. Variables included timeliness indicators, non-polio AFP (NPAFP) rates, stool adequacy and demographic, clinical, vaccination and laboratory characteristics. Trends were assessed using the Mann-Kendall test, and spatial patterns were illustrated using choropleth maps. Results: A total of 6409 AFP cases were reported, of which 5837 (91.1%) were confirmed as true AFP. The median age was 3 years (IQR: 1-7), with most cases occurring in children <5 years (59.3%) and males (57.8%). Timeliness indicators showed that 63% of cases were notified within 7 days, 93.4% were investigated within 48 hours and 76.5% of stool specimens were shipped within 3 days. Stool adequacy was 88.6% and 99.8% of samples arrived in good condition. The NPAFP rate averaged 3.4/100 000, meeting the ≥3.0 target in 5 of 8 years. Clinically, 90% of cases were community-identified; 91% had fever at onset, 86% showed rapid progression within 3 days and 80% had asymmetrical paralysis. Among cases with vaccination history, 77% had received ≥3 oral polio vaccine doses and 3% were unvaccinated. Of 6405 samples tested, 2% were classified as suspected poliovirus and 0.1% as mixed non-polio enterovirus and poliovirus. Among 823 followed-up cases, 30% had residual paralysis, 1% had died and 0.6% were lost to follow-up. District-level performance was variable and suboptimal, with averages of 63.4% districts achieving the NPAFP rate target, 74.8% stool adequacy and 49% both core indicators. Conclusion: Uganda's AFP surveillance system remains largely robust, though improvements in timeliness, regional equity and follow-up are needed to sustain progress towards polio eradication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.